

Marc P Bonaca

List of Publications by Citations

Source: <https://exaly.com/author-pdf/7114055/marc-p-bonaca-publications-by-citations.pdf>

Version: 2024-04-19

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

172
papers

12,908
citations

47
h-index

112
g-index

240
ext. papers

16,747
ext. citations

9.5
avg, IF

6.32
L-index

#	Paper	IF	Citations
172	Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2019 , 380, 347-357	59.2	2455
171	SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. <i>Lancet, The</i> , 2019 , 393, 31-39	40	1300
170	Long-term use of ticagrelor in patients with prior myocardial infarction. <i>New England Journal of Medicine</i> , 2015 , 372, 1791-800	59.2	1193
169	Vorapaxar in the secondary prevention of atherothrombotic events. <i>New England Journal of Medicine</i> , 2012 , 366, 1404-13	59.2	694
168	Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study. <i>Lancet Oncology, The</i> , 2018 , 19, 1579-1589	21.7	395
167	Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease: Insights From the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk). <i>Circulation</i> , 2018 , 137, 338-350	16.7	348
166	Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors For Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus. <i>Circulation</i> , 2019 , 139, 2022-2031	16.7	345
165	Effect of darapladib on major coronary events after an acute coronary syndrome: the SOLID-TIMI 52 randomized clinical trial. <i>JAMA - Journal of the American Medical Association</i> , 2014 , 312, 1006-15	27.4	285
164	Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus. <i>Circulation</i> , 2019 , 139, 2528-2536	16.7	283
163	Rivaroxaban in Peripheral Artery Disease after Revascularization. <i>New England Journal of Medicine</i> , 2020 , 382, 1994-2004	59.2	248
162	Long-term dual antiplatelet therapy for secondary prevention of cardiovascular events in the subgroup of patients with previous myocardial infarction: a collaborative meta-analysis of randomized trials. <i>European Heart Journal</i> , 2016 , 37, 390-9	9.5	232
161	Ticagrelor for Prevention of Ischemic Events After Myocardial Infarction in Patients With Peripheral Artery Disease. <i>Journal of the American College of Cardiology</i> , 2016 , 67, 2719-2728	15.1	225
160	Vorapaxar in patients with peripheral artery disease: results from TRA2{degrees}P-TIMI 50. <i>Circulation</i> , 2013 , 127, 1522-9, 1529e1-6	16.7	208
159	Vorapaxar for secondary prevention of thrombotic events for patients with previous myocardial infarction: a prespecified subgroup analysis of the TRA 2{degrees}P-TIMI 50 trial. <i>Lancet, The</i> , 2012 , 380, 1317-24	40	177
158	Evaluation of a novel antiplatelet agent for secondary prevention in patients with a history of atherosclerotic disease: design and rationale for the Thrombin-Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events (TRA 2 degrees P)-TIMI 50 trial. <i>American Heart Journal</i> , 2009 , 158, 225-244	4.9	157
157	Myocarditis in the Setting of Cancer Therapeutics: Proposed Case Definitions for Emerging Clinical Syndromes in Cardio-Oncology. <i>Circulation</i> , 2019 , 140, 80-91	16.7	153
156	Effect of Losmapimod on Cardiovascular Outcomes in Patients Hospitalized With Acute Myocardial Infarction: A Randomized Clinical Trial. <i>JAMA - Journal of the American Medical Association</i> , 2016 , 315, 1591-9	27.4	144

155	Cardiovascular Safety of Lorcaserin in Overweight or Obese Patients. <i>New England Journal of Medicine</i> , 2018 , 379, 1107-1117	59.2	143
154	Dapagliflozin and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus and Previous Myocardial Infarction. <i>Circulation</i> , 2019 , 139, 2516-2527	16.7	142
153	Reduction in Ischemic Events With Ticagrelor in Diabetic Patients With Prior Myocardial Infarction in PEGASUS-TIMI 54. <i>Journal of the American College of Cardiology</i> , 2016 , 67, 2732-2740	15.1	141
152	Effect of the novel thienopyridine prasugrel compared with clopidogrel on spontaneous and procedural myocardial infarction in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis in Myocardial Infarction 38: an	16.7	137
151	American College of Cardiology/American Heart Association/European Society of Cardiology/World Heart Federation universal definition of myocardial infarction classification system and the risk of cardiovascular death: observations from the TRITON-TIMI 38 trial (Trial to Assess Improvement in	16.7	129
150	Acute Limb Ischemia and Outcomes With Vorapaxar in Patients With Peripheral Artery Disease: Results From the Trial to Assess the Effects of Vorapaxar in Preventing Heart Attack and Stroke in Patients With Atherosclerosis-Thrombolysis in Myocardial Infarction 50 (TRA2IP-TIMI 50).	16.7	120
149	Role of ST2 in non-ST-elevation acute coronary syndrome in the MERLIN-TIMI 36 trial. <i>Clinical Chemistry</i> , 2012 , 58, 257-66	5.5	115
148	Prospective evaluation of the prognostic implications of improved assay performance with a sensitive assay for cardiac troponin I. <i>Journal of the American College of Cardiology</i> , 2010 , 55, 2118-24	15.1	105
147	Ischaemic risk and efficacy of ticagrelor in relation to time from P2Y12 inhibitor withdrawal in patients with prior myocardial infarction: insights from PEGASUS-TIMI 54. <i>European Heart Journal</i> , 2016 , 37, 1133-42	9.5	103
146	Growth differentiation factor-15 and risk of recurrent events in patients stabilized after acute coronary syndrome: observations from PROVE IT-TIMI 22. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2011 , 31, 203-10	9.4	103
145	Atherothrombotic Risk Stratification and the Efficacy and Safety of Vorapaxar in Patients With Stable Ischemic Heart Disease and Previous Myocardial Infarction. <i>Circulation</i> , 2016 , 134, 304-13	16.7	102
144	Effect of Dapagliflozin on Atrial Fibrillation in Patients With Type 2 Diabetes Mellitus: Insights From the DECLARE-TIMI 58 Trial. <i>Circulation</i> , 2020 , 141, 1227-1234	16.7	97
143	The design and rationale for the Dapagliflozin Effect on Cardiovascular Events (DECLARE)-TIMI 58 Trial. <i>American Heart Journal</i> , 2018 , 200, 83-89	4.9	89
142	Platelet Inhibition With Ticagrelor 60 mg Versus 90 mg Twice Daily in the PEGASUS-TIMI 54 Trial. <i>Journal of the American College of Cardiology</i> , 2016 , 67, 1145-1154	15.1	82
141	DECLARE-TIMI 58: Participants' baseline characteristics. <i>Diabetes, Obesity and Metabolism</i> , 2018 , 20, 1107-1108	4.9	80
140	Efficacy and safety of vorapaxar in patients with prior ischemic stroke. <i>Stroke</i> , 2013 , 44, 691-8	6.7	80
139	Design and rationale for the Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin-Thrombolysis in Myocardial Infarction 54 (PEGASUS-TIMI 54) trial. <i>American Heart Journal</i> , 2014 , 167, 437-444.e5	4.9	74
138	Rationale and design for the Vascular Outcomes study of ASA along with rivaroxaban in endovascular or surgical limb revascularization for peripheral artery disease (VOYAGER PAD). <i>American Heart Journal</i> , 2018 , 199, 83-91	4.9	71

137	Long-term Tolerability of Ticagrelor for the Secondary Prevention of Major Adverse Cardiovascular Events: A Secondary Analysis of the PEGASUS-TIMI 54 Trial. <i>JAMA Cardiology</i> , 2016 , 1, 425-32	16.2	70
136	Pharmacological treatment and current management of peripheral artery disease. <i>Circulation Research</i> , 2015 , 116, 1579-98	15.7	66
135	Prognostic performance of multiple biomarkers in patients with non-ST-segment elevation acute coronary syndrome: analysis from the MERLIN-TIMI 36 trial (Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST-Elevation Acute Coronary Syndromes-Thrombolysis In Myocardial Infarction 36). <i>Journal of the American College of Cardiology</i> , 2014 , 63, 1644-53	15.1	64
134	Odanacatib for the treatment of postmenopausal osteoporosis: results of the LOFT multicentre, randomised, double-blind, placebo-controlled trial and LOFT Extension study. <i>Lancet Diabetes and Endocrinology</i> , 2019 , 7, 899-911	18.1	61
133	Vorapaxar in patients with diabetes mellitus and previous myocardial infarction: findings from the thrombin receptor antagonist in secondary prevention of atherothrombotic ischemic events-TIMI 50 trial. <i>Circulation</i> , 2015 , 131, 1047-53	16.7	59
132	Prognostic performance of a high-sensitivity cardiac troponin I assay in patients with non-ST-elevation acute coronary syndrome. <i>Clinical Chemistry</i> , 2014 , 60, 158-64	5.5	59
131	Polyvascular disease, type 2 diabetes, and long-term vascular risk: a secondary analysis of the IMPROVE-IT trial. <i>Lancet Diabetes and Endocrinology</i> , 2018 , 6, 934-943	18.1	58
130	Efficacy and safety of vorapaxar as approved for clinical use in the United States. <i>Journal of the American Heart Association</i> , 2015 , 4, e001505	6	55
129	Efficacy and safety of ticagrelor for long-term secondary prevention of atherothrombotic events in relation to renal function: insights from the PEGASUS-TIMI 54 trial. <i>European Heart Journal</i> , 2016 , 37, 400-8	9.5	54
128	Microvascular Disease, Peripheral Artery Disease, and Amputation. <i>Circulation</i> , 2019 , 140, 449-458	16.7	53
127	Efficacy and Safety of Ticagrelor Over Time in Patients With Prior MI in PEGASUS-TIMI 54. <i>Journal of the American College of Cardiology</i> , 2017 , 70, 1368-1375	15.1	50
126	Long-Term Use of Ticagrelor in Patients with Prior Myocardial Infarction. <i>New England Journal of Medicine</i> , 2015 , 373, 1274-5	59.2	48
125	Prospective evaluation of pregnancy-associated plasma protein-a and outcomes in patients with acute coronary syndromes. <i>Journal of the American College of Cardiology</i> , 2012 , 60, 332-8	15.1	46
124	Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial. <i>Lancet, The</i> , 2018 , 392, 2269-2279	40	46
123	Antithrombotics in acute coronary syndromes. <i>Journal of the American College of Cardiology</i> , 2009 , 54, 969-84	15.1	44
122	Central obesity and cardiovascular outcomes in patients with acute coronary syndrome: observations from the MERLIN-TIMI 36 trial. <i>Heart</i> , 2011 , 97, 1782-7	5.1	43
121	Recurrent Aortic Dissection: Observations From the International Registry of Aortic Dissection. <i>Circulation</i> , 2016 , 134, 1013-1024	16.7	42
120	Ticagrelor for Secondary Prevention of Atherothrombotic Events in Patients With Multivessel Coronary Disease. <i>Journal of the American College of Cardiology</i> , 2018 , 71, 489-496	15.1	41

119	Coronary stent thrombosis with vorapaxar versus placebo: results from the TRA 2 ^o P-TIMI 50 trial. <i>Journal of the American College of Cardiology</i> , 2014 , 64, 2309-17	15.1	37
118	Potent P2Y Inhibitors in Men Versus Women: A Collaborative Meta-Analysis of Randomized Trials. <i>Journal of the American College of Cardiology</i> , 2017 , 69, 1549-1559	15.1	36
117	Comparative Efficacy of Endovascular Revascularization Versus Supervised Exercise Training in Patients With Intermittent Claudication: Meta-Analysis of Randomized Controlled Trials. <i>JACC: Cardiovascular Interventions</i> , 2017 , 10, 712-724	5	34
116	Prevention of Stroke with Ticagrelor in Patients with Prior Myocardial Infarction: Insights from PEGASUS-TIMI 54 (Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin-Thrombolysis in Myocardial Infarction 54). <i>Circulation</i> , 2016 , 134, 861-71	16.7	34
115	Randomized Controlled Trial of Social Media: Effect of Increased Intensity of the Intervention. <i>Journal of the American Heart Association</i> , 2016 , 5,	6	34
114	The Effect of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibition on the Risk of Venous Thromboembolism. <i>Circulation</i> , 2020 , 141, 1600-1607	16.7	32
113	Diagnosis and management of acute aortic syndromes: dissection, intramural hematoma, and penetrating aortic ulcer. <i>Current Cardiology Reports</i> , 2014 , 16, 536	4.2	32
112	Efficacy and Safety of Vorapaxar With and Without a Thienopyridine for Secondary Prevention in Patients With Previous Myocardial Infarction and No History of Stroke or Transient Ischemic Attack: Results from TRA 2 ^o P-TIMI 50. <i>Circulation</i> , 2015 , 132, 1871-9	16.7	30
111	New ischemic stroke and outcomes with vorapaxar versus placebo: results from the TRA 2 ^o P-TIMI 50 trial. <i>Journal of the American College of Cardiology</i> , 2014 , 64, 2318-26	15.1	29
110	Osteoprotegerin and cardiovascular mortality in patients with non-ST elevation acute coronary syndromes. <i>Heart</i> , 2012 , 98, 786-91	5.1	29
109	Peripheral Revascularization in Patients With Peripheral Artery Disease With Vorapaxar: Insights From the TRA 2 ^o P-TIMI 50 Trial. <i>JACC: Cardiovascular Interventions</i> , 2016 , 9, 2157-2164	5	26
108	Evaluation of the diagnostic performance of current and next-generation assays for cardiac troponin I in the BWH-TIMI ED Chest Pain Study. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2013 , 2, 195-202	4.3	24
107	Cardiac mortality in patients randomised to elective coronary revascularisation plus medical therapy or medical therapy alone: a systematic review and meta-analysis. <i>European Heart Journal</i> , 2021 , 42, 4638-4651	9.5	21
106	Lorcaserin and Renal Outcomes in Obese and Overweight Patients in the CAMELLIA-TIMI 61 Trial. <i>Circulation</i> , 2019 , 139, 366-375	16.7	21
105	Consistent platelet inhibition with ticagrelor 60 mg twice-daily following myocardial infarction regardless of diabetes status. <i>Thrombosis and Haemostasis</i> , 2017 , 117, 940-947	7	20
104	Defining a role for novel biomarkers in acute coronary syndromes. <i>Clinical Chemistry</i> , 2008 , 54, 1424-31	5.5	20
103	Baseline adiponectin concentration and clinical outcomes among patients with diabetes and recent acute coronary syndrome in the EXAMINE trial. <i>Diabetes, Obesity and Metabolism</i> , 2017 , 19, 962-969	6.7	19
102	External validation of the TIMI risk score for secondary cardiovascular events among patients with recent myocardial infarction. <i>Atherosclerosis</i> , 2018 , 272, 80-86	3.1	19

101	Long-term ticagrelor for secondary prevention in patients with prior myocardial infarction and no history of coronary stenting: insights from PEGASUS-TIMI 54. <i>European Heart Journal</i> , 2020 , 41, 1625-1632	9.5	19
100	Efficacy and safety with ticagrelor in patients with prior myocardial infarction in the approved European label: insights from PEGASUS-TIMI 54. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2019 , 5, 200-206	6.4	17
99	Rivaroxaban and Aspirin in Peripheral Artery Disease Lower Extremity Revascularization: Impact of Concomitant Clopidogrel on Efficacy and Safety. <i>Circulation</i> , 2020 , 142, 2219-2230	16.7	17
98	Cost-Effectiveness of Long-Term Ticagrelor in Patients With Prior Myocardial Infarction: Results From the PEGASUS-TIMI 54 Trial. <i>Journal of the American College of Cardiology</i> , 2017 , 70, 527-538	15.1	17
97	High-Sensitivity Troponin I in Stable Patients with Atherosclerotic Disease in the TRA 2P - TIMI 50 Trial. <i>Clinical Chemistry</i> , 2017 , 63, 307-315	5.5	16
96	Gut Microbiota-Dependent Trimethylamine N-oxide and Cardiovascular Outcomes in Patients With Prior Myocardial Infarction: A Nested Case Control Study From the PEGASUS-TIMI 54 Trial. <i>Journal of the American Heart Association</i> , 2020 , 9, e015331	6	16
95	International Validation of the Thrombolysis in Myocardial Infarction (TIMI) Risk Score for Secondary Prevention in Post-MI Patients: A Collaborative Analysis of the Chronic Kidney Disease Prognosis Consortium and the Risk Validation Scientific Committee. <i>Journal of the American Heart Association</i> , 2018 , 7,	6	16
94	Evaluation of the diagnostic performance of heart-type fatty acid binding protein in the BWH-TIMI ED chest pain study. <i>Journal of Thrombosis and Thrombolysis</i> , 2013 , 36, 361-7	5.1	16
93	Diagnostic evaluation of the MRP-8/14 for the emergency assessment of chest pain. <i>Journal of Thrombosis and Thrombolysis</i> , 2012 , 34, 229-34	5.1	16
92	Dapagliflozin and Cardiac, Kidney, and Limb Outcomes in Patients With and Without Peripheral Artery Disease in DECLARE-TIMI 58. <i>Circulation</i> , 2020 , 142, 734-747	16.7	16
91	Prevalence and Outcomes of Polyvascular (Coronary, Peripheral, or Cerebrovascular) Disease in Patients With Diabetes Mellitus (From the SAVOR-TIMI 53 Trial). <i>American Journal of Cardiology</i> , 2019 , 123, 145-152	3	16
90	Effect of vorapaxar on cardiovascular and limb outcomes in patients with peripheral artery disease with and without coronary artery disease: Analysis from the TRA 2P-TIMI 50 trial. <i>Vascular Medicine</i> , 2020 , 25, 124-132	3.3	15
89	Prognostic implications of low level cardiac troponin elevation using high-sensitivity cardiac troponin T. <i>Clinical Cardiology</i> , 2015 , 38, 230-5	3.3	14
88	Rationale and design for the study of rivaroxaban to reduce thrombotic events, hospitalization and death in outpatients with COVID-19: The PREVENT-HD study. <i>American Heart Journal</i> , 2021 , 235, 12-23	4.9	14
87	Prognostic performance of a high-sensitivity assay for cardiac troponin I after non-ST elevation acute coronary syndrome: Analysis from MERLIN-TIMI 36. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2015 , 4, 431-40	4.3	13
86	Safety of dapagliflozin in a broad population of patients with type 2 diabetes: Analyses from the DECLARE-TIMI 58 study. <i>Diabetes, Obesity and Metabolism</i> , 2020 , 22, 1357-1368	6.7	13
85	SCH 530348: a novel oral thrombin receptor antagonist. <i>Future Cardiology</i> , 2009 , 5, 435-42	1.3	13
84	Clinical Application of a Novel Genetic Risk Score for Ischemic Stroke in Patients With Cardiometabolic Disease. <i>Circulation</i> , 2021 , 143, 470-478	16.7	13

83	Nonculprit Lesion Myocardial Infarction Following Percutaneous Coronary Intervention in Patients With Acute Coronary Syndrome. <i>Journal of the American College of Cardiology</i> , 2020 , 75, 1095-1106	15.1	12
82	Clinical Application of High-Sensitivity Troponin Testing in the Atherosclerotic Cardiovascular Disease Framework of the Current Cholesterol Guidelines. <i>JAMA Cardiology</i> , 2020 , 5, 1255-1262	16.2	12
81	Universal Classification System Type of Incident Myocardial Infarction in Patients With Stable Atherosclerosis: Observations From Thrombin Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events (TRA 2 ^{TP})-TIMI 50. <i>Journal of the American Heart Association</i> , 2016 , 5,	6	12
80	New cardiovascular prevention guidelines: How to optimally manage dyslipidaemia and cardiovascular risk in 2021 in patients needing secondary prevention?. <i>Atherosclerosis</i> , 2021 , 319, 51-61	3.1	12
79	Serial Cardiac Troponin Measured Using a High-Sensitivity Assay in Stable Patients With Ischemic Heart Disease. <i>Journal of the American College of Cardiology</i> , 2016 , 68, 322-323	15.1	11
78	Pharmacokinetic-pharmacodynamic modelling of platelet response to ticagrelor in stable coronary artery disease and prior myocardial infarction patients. <i>British Journal of Clinical Pharmacology</i> , 2019 , 85, 413-421	3.8	11
77	Supervised Exercise Therapy for Symptomatic Peripheral Artery Disease Among Medicare Beneficiaries Between 2017 and 2018: Participation Rates and Outcomes. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2021 , 14, e007953	5.8	11
76	Frequency, Predictors, and Impact of Combined Antiplatelet Therapy on Venous Thromboembolism in Patients With Symptomatic Atherosclerosis. <i>Circulation</i> , 2018 , 137, 684-692	16.7	10
75	Clinical features, use of evidence-based therapies, and cardiovascular outcomes among patients with chronic kidney disease following non-ST-elevation acute coronary syndrome. <i>Clinical Cardiology</i> , 2014 , 37, 350-6	3.3	10
74	Contemporary Medical Management of Peripheral Artery Disease. <i>Circulation Research</i> , 2021 , 128, 1868-1884	13.4	10
73	Elevated concentration of placental growth factor (PlGF) and long term risk in patients with acute coronary syndrome in the PROVE IT-TIMI 22 trial. <i>Journal of Thrombosis and Thrombolysis</i> , 2012 , 34, 222-8	5.1	9
72	Response by Bonaca and Sabatine to Letters Regarding Article, "Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease: Insights From the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk)". <i>Circulation</i> , 2019 , 139, 2022-2023	16.7	9
71	Diagnostic performance of copeptin in patients with acute nontraumatic chest pain: BWH-TIMI ED chest pain study. <i>Clinical Cardiology</i> , 2014 , 37, 227-32	3.3	8
70	Hemodynamic significance of periprocedural myocardial injury assessed with N-terminal pro-B-type natriuretic peptide after percutaneous coronary intervention in patients with stable and unstable coronary artery disease (from the JUMBO-TIMI 26 trial). <i>American Journal of Cardiology</i> , 2007 , 99, 344-8	3	8
69	Atherothrombotic risk stratification after acute myocardial infarction: The Thrombolysis in Myocardial Infarction Risk Score for Secondary Prevention in the light of the French Registry of Acute ST Elevation or non-ST Elevation Myocardial Infarction registries. <i>Clinical Cardiology</i> , 2019 , 42, 227-234	3.3	8
68	Vorapaxar in patients with coronary artery bypass grafting: Findings from the TRA 2 ^{TP} -TIMI 50 trial. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2017 , 6, 164-172	4.3	7
67	Prognostic role of GDF-15 across the spectrum of clinical risk in patients with NSTEMI-ACS. <i>Clinical Chemistry and Laboratory Medicine</i> , 2019 , 57, 1084-1092	5.9	7
66	Antiplatelet Therapy for Long-term Secondary Prevention After Myocardial Infarction. <i>JAMA Cardiology</i> , 2016 , 1, 627-8	16.2	7

65	Acute dissection of the descending aorta: a case report and review of the literature. <i>Cardiology and Therapy</i> , 2013 , 2, 199-213	2.8	7
64	TCT-78 Efficacy of Long-Term Ticagrelor in Stented Patients in PEGASUS-TIMI 54. <i>Journal of the American College of Cardiology</i> , 2015 , 66, B36	15.1	7
63	Recombinant human Lecithin-Cholesterol acyltransferase in patients with atherosclerosis: Phase 2a primary results and phase 2b design. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021 ,	6.4	7
62	Exercise Training and Revascularization in the Management of Symptomatic Peripheral Artery Disease. <i>JACC Basic To Translational Science</i> , 2021 , 6, 174-188	8.7	7
61	Reduction in Subtypes and Sizes of Myocardial Infarction With Ticagrelor in PEGASUS-TIMI 54. <i>Journal of the American Heart Association</i> , 2018 , 7, e009260	6	7
60	Outcome associated with prescription of cardiac rehabilitation according to predicted risk after acute myocardial infarction: Insights from the FAST-MI registries. <i>Archives of Cardiovascular Diseases</i> , 2019 , 112, 459-468	2.7	6
59	Total Ischemic Event Reduction With Rivaroxaban After Peripheral Arterial Revascularization in the VOYAGER PAD Trial. <i>Journal of the American College of Cardiology</i> , 2021 , 78, 317-326	15.1	6
58	Appropriate secondary prevention and clinical outcomes after acute myocardial infarction according to atherothrombotic risk stratification: The FAST-MI 2010 registry. <i>European Journal of Preventive Cardiology</i> , 2019 , 26, 411-419	3.9	6
57	Efficacy and safety of more potent antiplatelet therapy with vorapaxar in patients with impaired renal function. <i>Journal of Thrombosis and Thrombolysis</i> , 2019 , 47, 353-360	5.1	6
56	Predictors, Type, and Impact of Bleeding on the Net Clinical Benefit of Long-Term Ticagrelor in Stable Patients With Prior Myocardial Infarction. <i>Journal of the American Heart Association</i> , 2021 , 10, e017008	6	6
55	Contemporary Review of Antithrombotic Therapy in Peripheral Artery Disease. <i>Circulation: Cardiovascular Interventions</i> , 2020 , 13, e009584	6	5
54	Effect of evolocumab on acute arterial events across all vascular territories : results from the FOURIER trial. <i>European Heart Journal</i> , 2021 ,	9.5	5
53	Outcomes in Stable Patients With Previous Atherothrombotic Events Receiving Vorapaxar Who Experience a New Acute Coronary Event (from TRA2P-TIMI 50). <i>American Journal of Cardiology</i> , 2016 , 117, 1055-8	3	4
52	Studying the coagulopathy of COVID-19. <i>Lancet, The</i> , 2021 ,	4.0	4
51	Reduction in Acute Limb Ischemia With Rivaroxaban Versus Placebo in Peripheral Artery Disease After Lower Extremity Revascularization: Insights From VOYAGER PAD. <i>Circulation</i> , 2021 , 144, 1831-1841	16.7	4
50	Effectiveness of Blood Lipid Management in Patients With Peripheral Artery Disease. <i>Journal of the American College of Cardiology</i> , 2021 , 77, 3016-3027	15.1	4
49	Vorapaxar for secondary prevention in the elderly with peripheral artery disease: Insights from the TRA 2P-TIMI 50 trial. <i>Vascular Medicine</i> , 2019 , 24, 159-161	3.3	3
48	Patterns of long-term thienopyridine therapy and outcomes in patients with acute coronary syndrome treated with coronary stenting: Observations from the TIMI-38 Coronary Stent Registry. <i>Clinical Cardiology</i> , 2014 , 37, 293-9	3.3	3

47	Response to Letter Regarding Articles, Long-Term Cardiovascular Mortality After Procedure-Related or Spontaneous Myocardial Infarction in Patients With Non-ST-Segment Elevation Acute Coronary Syndrome: A Collaborative Analysis of Individual Patient Data From the FRISC II, ICTUS, and RITA-3 Trials (FIR) and American College of Cardiology/American Heart	16.7	3
46	Safety and Effectiveness of Paclitaxel Drug-Coated Devices in Peripheral Artery Revascularization: Insights From VOYAGER PAD. <i>Journal of the American College of Cardiology</i> , 2021 , 78, 1768-1778	15.1	3
45	No Significant Relationship Between Ticagrelor and Sleep Apnea in Large, Randomized, Blinded Trials. <i>JACC: Cardiovascular Interventions</i> , 2020 , 13, 1012-1014	5	3
44	Cardiovascular Biomarkers and Heart Failure Risk in Stable Patients With Atherothrombotic Disease: A Nested Biomarker Study From TRA 2P-TIMI 50. <i>Journal of the American Heart Association</i> , 2021 , 10, e018673	6	3
43	Diabetes Mellitus and Risk Stratification After Peripheral Artery Revascularization. <i>Journal of the American College of Cardiology</i> , 2021 , 77, 2867-2869	15.1	3
42	Sex, Permanent Drug Discontinuation, and Study Retention in Clinical Trials: Insights From the TIMI trials. <i>Circulation</i> , 2021 , 143, 685-695	16.7	3
41	Low-dose rivaroxaban plus aspirin in older patients with peripheral artery disease undergoing acute limb revascularization: insights from the VOYAGER PAD trial. <i>European Heart Journal</i> , 2021 , 42, 4040-4048	8.5	3
40	Society for Vascular Surgery Appropriate Use Criteria for Management of Intermittent Claudication.. <i>Journal of Vascular Surgery</i> , 2022 ,	3.5	3
39	Antiplatelet Therapy for Secondary Prevention After Acute Myocardial Infarction. <i>Interventional Cardiology Clinics</i> , 2017 , 6, 119-129	1.4	2
38	Caffeinated Beverage Intake, Dyspnea With Ticagrelor, and Cardiovascular Outcomes: Insights From the PEGASUS-TIMI 54 Trial. <i>Journal of the American Heart Association</i> , 2020 , 9, e015785	6	2
37	Subclavian stenosis causing angina after coronary artery bypass grafting. <i>Medical Journal of Australia</i> , 2009 , 190, 331-2	4	2
36	Acute Aortic Syndromes. <i>Cardiology Clinics</i> , 2021 , 39, 495-503	2.5	2
35	Descending Aortic Dissection, Penetrating Aortic Ulcer, and Intramural Hematoma (Acute and Chronic) Including Kommerell's Diverticulum 2019 , 149-160		2
34	Efficacy and safety of vorapaxar for secondary prevention in low body weight in patients with atherosclerosis: analyses from the TRA 2P-TIMI 50 Trial. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2019 , 2048872619883354	4.3	2
33	Effect of Rivaroxaban and Aspirin in Patients With Peripheral Artery Disease Undergoing Surgical Revascularization: Insights From the VOYAGER PAD Trial. <i>Circulation</i> , 2021 , 144, 1104-1116	16.7	2
32	Improvement in walking impairment following surgical and endovascular revascularization: Insights from VOYAGER PAD.. <i>Vascular Medicine</i> , 2022 , 1358863X221085606	3.3	2
31	Utility of multimodality imaging in myopericarditis with aortitis. <i>Journal of Nuclear Cardiology</i> , 2017 , 24, 1103-1106	2.1	1
30	Tackling Elevated Risk in PAD: Focus on Antithrombotic and Lipid Therapy for PAD. <i>Current Cardiology Reports</i> , 2020 , 22, 13	4.2	1

29	Reply: Cost-Effectiveness of Long-Term Ticagrelor in Patients With Prior Myocardial Infarction: Analysis by Subgroups. <i>Journal of the American College of Cardiology</i> , 2018 , 71, 108	15.1	1
28	Management of asymptomatic carotid artery stenosis. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2013 , 15, 252-63	2.1	1
27	Glycoprotein IIb-IIIa inhibitors in the emergency department for patients with non-ST-elevation acute coronary syndromes: principles and practices. <i>Journal of Emergency Medicine</i> , 2009 , 36, 162-70	1.5	1
26	Antithrombotics in acute coronary syndromes: updates from the past year. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2010 , 12, 84-99	2.1	1
25	Abstract 14170: Reduction in Venous Thromboembolism With Rivaroxaban versus Placebo in Peripheral Artery Disease After Lower Extremity Revascularization: Insights From VOYAGER PAD. <i>Circulation</i> , 2020 , 142,	16.7	1
24	Abstract 17116: Incidence and Costs of Major Atherothrombotic Vascular Events Among Patients With Peripheral Artery Disease After Revascularization. <i>Circulation</i> , 2020 , 142,	16.7	1
23	Rationale and design of a study to assess the safety and efficacy of rNAPc2 in COVID-19: the Phase 2b ASPEN-COVID-19 trial.. <i>American Heart Journal</i> , 2022 , 246, 136-136	4.9	1
22	Antithrombotic strategies for patients with coronary and lower extremity peripheral artery diseases: a narrative review. <i>Expert Review of Cardiovascular Therapy</i> , 2020 , 18, 881-889	2.5	1
21	Medical Therapy for Secondary Prevention of Atherothrombotic Events in Peripheral Artery Disease. <i>Heart International</i> , 2021 , 15, 14	0.3	1
20	Genetic Risk Score to Identify Risk of Venous Thromboembolism in Patients With Cardiometabolic Disease. <i>Circulation Genomic and Precision Medicine</i> , 2021 , 14, e003006	5.2	1
19	Extended dual antiplatelet therapy with ticagrelor 60 mg in patients with prior myocardial infarction: The design of ALETHEIA, a multi-country observational study. <i>Clinical Cardiology</i> , 2021 , 44, 1333-1343	3.3	1
18	Rivaroxaban in Patients With Recent Peripheral Artery Revascularization and Renal Impairment: The VOYAGER PAD Trial. <i>Journal of the American College of Cardiology</i> , 2021 , 78, 757-759	15.1	1
17	Incidence of Major Atherothrombotic Vascular Events among Patients with Peripheral Artery Disease after Revascularization. <i>Annals of Vascular Surgery</i> , 2021 , 75, 217-226	1.7	1
16	Long-Term Ticagrelor in Patients With Prior Coronary Stenting in the PEGASUS-TIMI 54 Trial. <i>Journal of the American Heart Association</i> , 2021 , 10, e020446	6	1
15	Prospective Cardiovascular Surveillance of Immune Checkpoint Inhibitor-Based Combination Therapy in Patients With Advanced Renal Cell Cancer: Data From the Phase III JAVELIN Renal 101 Trial.. <i>Journal of Clinical Oncology</i> , 2022 , JCO2101806	2.2	1
14	Impact of Polyvascular Disease and Diabetes on Limb and Cardiovascular Risk in Peripheral Artery Disease.. <i>Journal of the American College of Cardiology</i> , 2022 , 79, 1781-1783	15.1	1
13	Call for Formalized Pathways in Vascular Medicine Training. <i>Journal of the American College of Cardiology</i> , 2022 , 79, 2129-2139	15.1	1
12	Ticagrelor for acute coronary syndromes. <i>Expert Review of Cardiovascular Therapy</i> , 2013 , 11, 1473-84	2.5	0

11	Vorapaxar for Prevention of Major Adverse Cardiovascular and Limb Events in Peripheral Artery Disease.. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2022 , 27, 10742484211056115	2.6	○
10	Challenges of Long-term Dual Antiplatelet Therapy Use Following Acute Coronary Syndromes: Patient Selection for Long-term DAPT After ACS.. <i>American Heart Journal</i> , 2021 , 246, 44-44	4.9	○
9	Efficacy and Safety of Vorapaxar by Intensity of Background Lipid-Lowering Therapy in Patients With Peripheral Artery Disease: Insights From the TRA2P-TIMI 50 Trial. <i>Journal of the American Heart Association</i> , 2021 , 10, e021412	6	○
8	Healthcare resource utilization and costs of major atherothrombotic vascular events among patients with peripheral artery disease after revascularization. <i>Journal of Medical Economics</i> , 2021 , 24, 402-409	2.4	○
7	At-home sample collection is an effective strategy for diagnosis and management of symptomatic and asymptomatic SARS-CoV-2 carriers.. <i>BMC Infectious Diseases</i> , 2022 , 22, 443	4	○
6	American Heart Association Vascular Disease Strategically Focused Research Network. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2020 , 40, e47-e54	9.4	
5	Antithrombotic Therapy in Patients With Peripheral Artery Disease. <i>JAMA Cardiology</i> , 2016 , 1, 803-804	16.2	
4	Primary Stroke Prevention: Medical Therapy Versus Revascularization. <i>Interventional Cardiology Clinics</i> , 2014 , 3, 1-11	1.4	
3	Left ventricular thrombosis refractory to medical therapy. <i>Journal of the American College of Cardiology</i> , 2010 , 56, e37	15.1	
2	Novel views on finding an old foe: non-contrast computed tomography in the diagnosis of acute aortic syndromes. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2021 , 10, 976-977	4.3	
1	Ankle-Brachial Index for Risk Stratification in Patients With Symptomatic Peripheral Artery Disease With and Without Prior Lower Extremity Revascularization: Observations From the EUCLID Trial. <i>Circulation: Cardiovascular Interventions</i> , 2021 , 14, e009871	6	